Morglin-M Tablet ER is a once-daily, extended-release combination product containing metformin 500mg and teneligliptin 20mg, indicated for the treatment of type 2 diabetes mellitus. The tablet is designed to provide consistent and controlled release of the active ingredients over a 24-hour period. Metformin, an biguanide, improves insulin sensitivity and reduces glucose production in the liver, while teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases insulin secretion and reduces glucagon levels. The combination of metformin and teneligliptin provides a synergistic effect in improving glycemic control, reducing fasting plasma glucose levels, and minimizing the risk of hypoglycemia. Morglin-M Tablet ER is suitable for patients who require a combination of metformin and a DPP-4 inhibitor for the management of type 2 diabetes. It is available in a once-daily, easy-to-administer tablet form, with a low risk of gastrointestinal side effects. The recommended starting dose is one tablet once daily, with adjustments as needed to achieve the target glycemic control.

Dosage & How to Use

Dosage information not available. Please consult your doctor or pharmacist.